CLOV Biopharma Corp.
CLOV Biopharma Corp (“CBP”) was formed in early 2020 as the specific domicile for the advancement of research, development, and assessment of potential commercial viability of cedar leaf oil and cedar leaf oil vapour in the pharmaceutical, healthcare, and biotechnology sectors.
- Coronaviruses are a large family of viruses that cause respiratory illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever Acute Respiratory Syndrome (SARS).
- A novel coronavirus, “COVID-19”, is a new strain that had not previously been identified in humans.
Significant Global Economic Impact of
The death toll attributable to COVID-19 has surpassed that of the SARS epidemic.
Significant economic loss and global trade curtailment has already occurred in a relatively short period of time.
As of late February 2020, the COVID-19 outbreak has led to more than 77,000 illnesses and 2,600 deaths in China according to the WHO.
Outside of China, there have been over 2,000 reported cases across 30 countries with a total of 23 deaths.
Of relevance to coronavirus, Dr. Hudson conducted a study involving seven respiratory viruses that were tested for infectivity following exposure of dried virus films to certified cedar leaf oil vapour for various periods of time. All were susceptible, although the membrane containing viruses, like coronaviruses, were more vulnerable and were readily killed by short exposures without detrimental effects against the human cells.
Previously published manuscripts authored by Dr. Hudson have concluded that, in a laboratory setting, cedar leaf oil vapour was effective in killing (inactivating) several human respiratory viruses, including influenza virus, rhinovirus, adenovirus, as well as herpes simplex virus.
It was shown that short-term exposure to cedar leaf oil vapour had no adverse effects on cultured lung epithelial cells, thus confirming it is not cytotoxic.
Another interesting finding was that cedar leaf oil vapour also partly reduced the pro-inflammatory effect caused by rhinovirus infection, which means that it acts as a multifunctional therapeutic agent.
Chief Medical & Scientific Advisor
Dr. James Hudson, PhD
Dr. James Hudson, PhD, professor emeritus, Department of Pathology and Laboratory Medicine at the University of British Columbia.
Dr. Hudson holds a BSc (chemistry/physiology), and MSc (biochemistry), a PhD (molecular biology) and a postdoctoral fellowship in molecular virology.
Dr. Hudson is considered to be one of the foremost virologists in Canada and has completed various publications including “The activity of cedar leaf oil vapour against respiratory viruses” in the Journal of Applied Pharmaceutical Science and “The antimicrobial properties of cedar leaf (Thuja plicata) oil” in the International Journal of Respiratory Public Health.
Corporate Action Plan
Roadman Investment’s delivers significant value to entrepreneurs not just with the capital we provide but also with our team’s experience and passion.
Further validate previous scientific research of Dr. Hudson.
Obtain “proxy” COVID-19 for utilization in lab studies.
Continue assessment and testing of appropriate diffuser device(s) that have compatibility with cedar leaf oil vapour.
Assess joint-venture and/or cooperative partnership opportunities with international enterprises so as to expedite project advancement.
File patents and/or process patents where appropriate.
Ready to Grow your Business?
Our investment team is always looking for new companies to partner with. If your business requires capital to scale or you are ready for an exit we can help.
Start exploring your options and contact us today!
Why Invest in an Investment Firm?
Being a shareholder of an Investment firm is a natural way to diversify your portfolio and unlock market opportunities not available in traditional asset classes. While traditional asset classes can be an effective source of diversification investors can benefit from having exposure to high growth private companies that would otherwise be not available.
Sign up for our newsletter to download our presentation and learn more about what Roadman has to offer. Our presentation includes information on our:
Investment Philosophy & Criteria
THANK YOU FOR YOUR SUBSCRIPTION! Your download is available by clicking the link below.
Right Season is a Canadian venture capital and advisory firm listed on the TSX Venture Exchange (TSXV: LITT) that strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Right Season provides investment capital, and advisory services to both public and private companies we believe are poised for growth and exhibit strong potential for accretive shareholder value, and command market share in their respective industry sectors.
800-1199 West Hastings Street
Vancouver, BC V6E 3T5
+1 (833) 383-9900